Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes

Endocrine Journal

Volumn 51, Issue 6, 2004, Pages 537-544

  Hirata, Kumiko ^a   Kubo, Keiji ^a  

^a HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

Author keywords

Diabetic nephropathy; Diabetic retinopathy; N carboxymethyl lysine; Pentosidine

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; INSULIN; PENTOSIDINE;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ARGININE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LYSINE; MALE; MIDDLE AGED;

EID: 13444281983     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.51.537     Document Type: Article

References (21)

1. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H (1991) Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836-842.
2. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H (1995) Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44: 824-829.
3. Vlassara H, Palace MR (2002) Diabetes and advanced glycation endproducts. J Intern Med 251: 87-101.
4. Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hanssen KF (1997) Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 46: 661-665.
5. Onorato JM, Thorpe SR, Baynes JW (1998) Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann NY Acad Sci 854: 277-290.
6. Daimon M, Sugiyama K, Kameda W, Saitoh T, Oizumi T, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Kato T (2003) Increased urinary levels of pentosidine, pyrraline and acrolein adduct in type 2 diabetes. Endocr J 50: 61-67.
7. Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y (1998) Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pr 41: 131-137.
8. Sanaka T, Funaki T, Tanaka T, Hoshi S, Niwayama J, Taitoh T, Nishimura H, Higuchi C (2002) Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure. Nephron 91: 64-73.
9. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S, the DCCT Skin Collagen Ancillary Study Group (1999) Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes. Diabetes 48: 870-880.
10. Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 48: 1-9.
11. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C (1997) Oxidation conspires with glycation to generate noxious advanced glycation end products. Nephrol Dial Transplant 12: 255-258.
12. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW (1991) Formation of pentosidine during nonenzymatic browning of protein by glucose: Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266: 11654-11660.
13. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long standing IDDM. Diabetes 41: 1286-1292.
14. Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K (1999) Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10: 822-832.
15. Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T (1999) Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med 5: 393-405.
16. Endo M, Yanagisawa K, Tsuchida K (2001) Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy. Horm Metab Res 33: 317-322.
17. McCance DR, Dyer DG, Dunn JA (1993) Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470-2478.
18. Beisswenger PJ, Moore LL, Truls BJ, Curphey TJ (1993) Increased collagen-linked pentosidine and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 92: 212-217.
19. Tanji N, Markowitz GS, Fu C (2001) Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11: 1656-1666.
20. Vlassala H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. P Natl Acad Sci USA 91: 11704-11708.
21. Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H (2001) Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85: 87-91.